RATIONALE: The dopamine hypothesis for schizophrenia postulates overactivity of dopamine transmission in the basal ganglia. Most effective antipsychotic drugs block postsynaptic dopamine receptors, but in-vivo imaging studies have not been able to show changes in these receptors in drug-naive schizophrenics. OBJECTIVES: The presynaptic dopamine transporter (DAT) is thought to be an important regulator of synaptic dopamine concentration. We have used SPECT with (123)I-beta-CIT, which has a high affinity for DAT, in order to further examine the dopamine hypothesis for schizophrenia. METHODS: Six patients with chronic schizophrenia treated with classic dopamine D(2)-receptor blocking neuroleptics were investigated. The number of DAT binding sites in the basal ganglia was calculated and compared with five healthy volunteers and ten parkinsonian patients. RESULTS: The schizophrenic patients showed a 36-63% increase in DAT binding sites compared with the volunteers, whereas the parkinsonian patients showed a 57-96% decrease. The differences between the groups were highly significant (even after correction for different age composition within the groups). CONCLUSIONS: There was an increased number of DAT binding sites in the schizophrenic patients treated with dopamine D(2)-receptor blocking neuroleptics. This fits well with several recent reports that have shown increased volumes of basal ganglia in this patient category. It thus appears that there is an increased number of presynaptic dopamine releasing nerve terminals in the basal ganglia, possibly as a biological adaptation to counteract the postsynaptic dopamine D(2)-receptor blockade.
RATIONALE: The dopamine hypothesis for schizophrenia postulates overactivity of dopamine transmission in the basal ganglia. Most effective antipsychotic drugs block postsynaptic dopamine receptors, but in-vivo imaging studies have not been able to show changes in these receptors in drug-naive schizophrenics. OBJECTIVES: The presynaptic dopamine transporter (DAT) is thought to be an important regulator of synaptic dopamine concentration. We have used SPECT with (123)I-beta-CIT, which has a high affinity for DAT, in order to further examine the dopamine hypothesis for schizophrenia. METHODS: Six patients with chronic schizophrenia treated with classic dopamine D(2)-receptor blocking neuroleptics were investigated. The number of DAT binding sites in the basal ganglia was calculated and compared with five healthy volunteers and ten parkinsonianpatients. RESULTS: The schizophrenicpatients showed a 36-63% increase in DAT binding sites compared with the volunteers, whereas the parkinsonianpatients showed a 57-96% decrease. The differences between the groups were highly significant (even after correction for different age composition within the groups). CONCLUSIONS: There was an increased number of DAT binding sites in the schizophrenicpatients treated with dopamine D(2)-receptor blocking neuroleptics. This fits well with several recent reports that have shown increased volumes of basal ganglia in this patient category. It thus appears that there is an increased number of presynaptic dopamine releasing nerve terminals in the basal ganglia, possibly as a biological adaptation to counteract the postsynaptic dopamine D(2)-receptor blockade.
Authors: M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis Journal: Biol Psychiatry Date: 2000-03-01 Impact factor: 13.382
Authors: M H Chakos; J A Lieberman; R M Bilder; M Borenstein; G Lerner; B Bogerts; H Wu; B Kinon; M Ashtari Journal: Am J Psychiatry Date: 1994-10 Impact factor: 18.112
Authors: M Laruelle; R M Baldwin; R T Malison; Y Zea-Ponce; S S Zoghbi; M S al-Tikriti; E H Sybirska; R C Zimmermann; G Wisniewski; J L Neumeyer Journal: Synapse Date: 1993-04 Impact factor: 2.562
Authors: H N Wagner; H D Burns; R F Dannals; D F Wong; B Langstrom; T Duelfer; J J Frost; H T Ravert; J M Links; S B Rosenbloom; S E Lukas; A V Kramer; M J Kuhar Journal: Science Date: 1983-09-23 Impact factor: 47.728
Authors: R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang Journal: Proc Natl Acad Sci U S A Date: 1993-12-15 Impact factor: 11.205
Authors: Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo Journal: Psychopharmacology (Berl) Date: 2006-09-22 Impact factor: 4.530
Authors: K R Kessler; N Hamscho; B Morales; C Menzel; F Barrero; F Vives; S Gispert; G Auburger Journal: J Neural Transm (Vienna) Date: 2005-03-23 Impact factor: 3.575
Authors: Michael E Talkowski; Kathleen L McCann; Michael Chen; Lora McClain; Mikhil Bamne; Joel Wood; Kodavali V Chowdari; Annie Watson; Konasale M Prasad; George Kirov; Lyudmilla Georgieva; Draga Toncheva; Hader Mansour; David A Lewis; Michael Owen; Michael O'Donovan; Panagiotis Papasaikas; Patrick Sullivan; Douglas Ruderfer; Jeffrey K Yao; Sherry Leonard; Pramod Thomas; Fabio Miyajima; John Quinn; A Javier Lopez; Vishwajit L Nimgaonkar Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-10-18 Impact factor: 3.568
Authors: James L Kennedy; Nian Xiong; Jinlong Yu; Clement C Zai; Jennie G Pouget; Jie Li; Kefu Liu; Hong Qing; Tao Wang; Eden Martin; Deborah L Levy; Zhicheng Lin Journal: Schizophr Bull Date: 2015-12-26 Impact factor: 9.306
Authors: Kao Chin Chen; Yen Kuang Yang; Oliver Howes; I Hui Lee; Sabine Landau; Tzung Lieh Yeh; Nan Tsing Chiu; Po See Chen; Ru Band Lu; Anthony S David; Elvira Bramon Journal: Schizophr Bull Date: 2011-12-08 Impact factor: 9.306